Arovella Therapeutics (ALA) Investor presentation summary

Investment highlights

• CAR-INKT platform is designed to support therapies across blood cancers, solid tumors and autoimmune disease.

• FDA accepted the IND for ALA-101; Phase 1 was expected to start in Oct 2026, with preliminary data expected early CY27.

• Platform thesis combines healthy-donor cells, off-the-shelf manufacturing and multiple doses per batch to improve scalability and reduce cost.

CAR-INKT differentiation

• Allogeneic iNKT cells are positioned as an off-the-shelf approach without gene editing, intended to preserve cell fitness and avoid GvHD-related editing complexity.

• CAR-INKT cells combine CAR targeting with natural targeting mechanisms, offering multiple ways to attack tumors and potentially reduce antigen escape.

• iNKT cells are presented as able to infiltrate tumors, kill pro-tumor cells and activate other immune cells, with potential relevance to solid tumors.

Manufacturing platform

• Semi-automated process starts with healthy donor blood, isolates and expands iNKT cells, engineers them with a CAR, then freezes the product for use.

• The lentiviral platform supports CAR engineering and is described as suitable for large-scale and late-phase clinical development.

• One CAR-INKT batch is presented as treating multiple patients, with patients potentially ready to dose within one week versus a 3–4 week wait for patient-specific CAR-T manufacturing.